American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. Washington, DC: American Psychiatric Assocation.
American Pychiatric Association Press (1992). ICD-10. The International Statistical Classification of Diseases and Related Health Problems: 1 and 2.
et al. (2011). DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biology, 12, R10.
ChaliseP., ChickenE. and McGeeD. (2011) Baseline age effect on parameter estimates in Cox models. Journal of Statistical Computation and Simulation, 82, 1767–1774.
et al. (2010). A comparative study to screen dementia and APOE genotypes in an ageing East African population. Neurobiol Aging, 31, 732–740.
et al. (2010). Association between APOE epsilon4 allele and vascular dementia: the Cache County study. Dementia and Geriatric Cognitive Disorders, 29, 248–253.
CorboR. M. and ScacchiR. (1999). Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?
Annals of Human Genetics, 63, 301–310.
et al. (2008). A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians. Ethnicity & Disease, 18, 427–433.
et al. (2012). DNase I sensitivity QTLs are a jamor determinant of human expression variation. Nature, 482, 390–394.
et al. (2000). Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology, 54, 240–242.
et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278, 1349–1356.
FinchC. E. and SapolskyR. M. (1999). The evolution of Alzheimer disease, the reproductive schedule, and APOE isoforms. Neurobiology of Aging, 20, 407–428.
FinchC. E. and StanfordC. B. (2004). Meat-adaptive genes and the evolution of slower aging in humans. Quarterly Review of Biology, 63, 301–310.
et al. (2006). APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Annals of Human Genetics, 59, 182–185.
HallK. S., GaoS., EmsleyC. L., OgunniyiA. O., MorganO. and HendrieH. C. (2000). Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites. International Journal of Geriatric Psychiatry, 15, 521–531.
et al. (2006) Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology, 66, 223–227.
et al. (1988). The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. Journal of the American Geriatrics Society, 36, 402–408.
et al. (2001). Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA, 285, 739–747.
et al. (2004). Alzheimer's disease, genes, and environment: the value of international studies. Canadian Journal of Psychiatry, 49, 92–99.
et al. (2006). The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures. International Psychogeriatrics, 18, 653–666.
et al. (2013). Homocysteine levels and dementia risk in Yoruba and African Americans. International Psychogeriatrics, 25, 1859–1866.
HixsonJ. E. and VernierD. T. (1990). Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of Lipid Research, 31, 545–548.
KnopmanD. S., MosleyT. H., CatellierD. J. and CokerL. H. (2009). Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dementia, 5, 207–214.
et al. (1998). Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke, 29, 388–398.
LeffondreK., TouraineC., HelmerC. and JolyP. (2013). Internal-censored time-to-event and competing risk with death: is the illness-death model more accurate than the Cox model?
International Journal of Epidemiology, 42, 1177–1186.
MartinG. M. (1999). APOE alleles and lipophylic pathogens. Neurobiol Aging, 20, 441–443.
McKhannG., DrachmanD., FolsteinM., KatzmanR., PriceD. and StadlanE. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.
et al. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159–1165.
et al. (2006). Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Archives of Neurology, 63, 431–434.
et al. (2011). Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama Study. Journal of the American Geriatrics Society, 59, 1074–1079.
et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA, 309, 1483–1492.
et al. (1997). Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Annals of Neurology, 42, 659–661.
SawyerK., Sachs-EricssonN., PreacherK. J. and BlazerD. G. (2009). Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. Gerontology, 55, 32–40.
StewartR., RussC., RichardsM., BrayneC., LovestoneS. and MannA. (2001). Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population. Dementia and Geriatric Cognitive Disorders, 12, 251–256.
et al. (2012). Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science, 337, 64–69.
et al. (2009). The genetic risk structure and history of Africans and African Americans. Science, 324, 1035–1044.
et al. (2011). Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans. Alzheimer Disease and Associated Disorders, 25, 4–10.